Failure of Inhaled Corticosteroids to Improve Small Airway Obstruction in Two Patients with Sarcoidosis

B. Herer

DOI: https://doi.org/10.1159/000049382

2002-02-01

Respiration

Abstract:Airway obstruction has been reported to be the most common pulmonary function abnormality in sarcoidosis and is mainly the consequence of a small airway involvement (SAO) [1], which has been shown to respond to oral or intravenous corticosteroids [2]. Because the side effects of these drugs may limit their use, inhaled corticosteroids (ICS) have been proposed in the therapy of sarcoidosis [3]. We report the cases of 2 patients with sarcoidosis whose SAO did not improve with ICS. The first patient was a 48-year-old white woman, a non-smoker, who reported having a cough and dyspnoea. She had been treated the year before in another hospital for pulmonary tuberculosis, though a bacteriological confirmation of tuberculosis was not made. A CT scan of the thorax showed mediastinal lymphadenopathy and infiltrates over both lungs. Endobronchial specimens obtained during fiberoptic bronchoscopy were normal. The BAL showed increased cell recovery (100,000 cells/ml of BAL fluid), an increased percentage of lymphocytes (36%) with a CD4/CD8 ratio of 2.21. Pulmonary function tests and the serum angiotensin-converting enzyme levels are given in table 1. A lymph node biopsy taken at mediastinoscopy showed non-caseating, epithelioid giant-cell sarcoid granulomas. Oral prednisolone was given, and the patient’s symptoms, chest radiograph appearance and SAO improved markedly. Inhaled beclomethasone was given as a maintenance treatment, but a relapse occurred 4 months later. Oral prednisolone was given, allowing a further improvement of the disease. The second patient was a 28-year-old white woman referred for evaluation because of an abnormal chest radiograph associated with a supraclavicular lymphadenopathy. Baseline pulmonary function tests are given in table 1. A diagnosis of sarcoidosis was established by mediastinoscopy with lymph node biopsy. No therapy was given. Five months later, she developed dyspnoea, a dry cough and malaise. Chest radiograph and CT scan of the thorax showed mediastinal lymphadenopathy. Inhaled beclomethasone was given, but a relapse occurred 17 months later. Oral prednisolone was given, leading to an improvement of the disease (table 1). These 2 patients had biopsy-proven sarcoidosis, and SAO was their main functional abnormality. In patient 1, a relapse of the disease during maintenance therapy with ICS occurred, whereas in patient 2, ICS were given first, but did not prevent the relapse of sarcoidosis. A few randomized, placebo-controlled studies have found clinical benefits of ICS in sarcoidosis [4–6]. The use of ICS when SAO is present could be warranted by the fact that sarcoid granulomas have a propensity for peribronchial locations [3]. However, the cases reported here show that ICS failed to improve SAO associated with bronchial sarcoid granulomas, while oral corticosteroids had a total or partial effect on this feature. Additional studies are needed to investigate this point.